{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:21:32Z","timestamp":1791235292757,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["No.SZZYSM202311018"],"award-info":[{"award-number":["No.SZZYSM202311018"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-024-03458-7","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T09:52:32Z","timestamp":1735033952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Associations of C-reactive protein to lymphocyte ratio and metabolic-dysfunction-associated steatotic liver disease: evidence from NHANES 2017\u20132018"],"prefix":"10.1186","volume":"24","author":[{"given":"Bowen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Ping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"6","key":"3458_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"2","key":"3458_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hep4.1134","volume":"2","author":"P NASR","year":"2018","unstructured":"NASR P, IGNATOVA S. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies [J]. Hepatol Commun. 2018;2(2):199\u2013210.","journal-title":"Hepatol Commun"},{"issue":"12","key":"3458_CR3","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"X LE M H, YEO Y H, LI","year":"2022","unstructured":"LE M H, YEO Y H, LI X, et al. 2019 global NAFLD prevalence: a systematic review and Meta-analysis [J]. Clin Gastroenterol Hepatol. 2022;20(12):2809\u2013e1728.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10290","key":"3458_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"RINELLAM POWELL E E, WONG V W","year":"2021","unstructured":"POWELL E E, WONG V W RINELLAM. Non-alcoholic fatty liver disease [J]. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"5","key":"3458_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"M ZES F E","year":"2022","unstructured":"M ZES F E, LEE J A, SELVARAJ E A, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis [J]. Gut. 2022;71(5):1006\u201319.","journal-title":"Gut"},{"issue":"6","key":"3458_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"G DAVISON B A, HARRISON S A, COTTER","year":"2020","unstructured":"DAVISON B A, HARRISON S A, COTTER G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials [J]. J Hepatol. 2020;73(6):1322\u201332.","journal-title":"J Hepatol"},{"issue":"4","key":"3458_CR7","first-page":"1080","volume":"165","author":"JJ WATTACHERIL","year":"2023","unstructured":"WATTACHERIL JJ, ABDELMALEK M F, LIM JK, et al. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease. Expert Rev [J] Gastroenterol. 2023;165(4):1080\u20138.","journal-title":"Expert Rev [J] Gastroenterol"},{"key":"3458_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcancer.2023.04.010","volume":"93","author":"SA POLYZOS","year":"2023","unstructured":"POLYZOS SA, VACHLIOTIS I D CHRYSAVGISL, et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma:insights in epidemiology, pathogenesis, imaging, prevention and therapy [J]. Semin Cancer Biol. 2023;93:20\u201335.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"3458_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in Chronic Liver diseases. Gastroenterology. 2018;155(3):629\u201347.","journal-title":"Gastroenterology"},{"issue":"16","key":"3458_CR10","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3390\/cells11162511","volume":"11","author":"N Nasiri-Ansari","year":"2022","unstructured":"Nasiri-Ansari N, Androutsakos T, Flessa CM, et al. Endothelial cell dysfunction and nonalcoholic fatty liver Disease (NAFLD): a concise review. Cells. 2022;11(16):2511.","journal-title":"Cells"},{"issue":"3","key":"3458_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.30506","volume":"70","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang XJ, Li H. The role of Innate Immune cells in nonalcoholic steatohepatitis. Hepatology. 2019;70(3):1026\u201337.","journal-title":"Hepatology"},{"key":"3458_CR12","doi-asserted-by":"crossref","unstructured":"Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024 Jan-Dec;16(1):2331460.","DOI":"10.1080\/19490976.2024.2331460"},{"issue":"138","key":"3458_CR13","first-page":"368","volume":"62","author":"X MA L N, LIU X Y, LUO","year":"2015","unstructured":"MA L N, LIU X Y, LUO X, et al. Serum high-sensitivity C-reactive protein are associated with HBV replication, liver damage and fibrosis in patients with chronic hepatitis B [J]. Hepatogastroenterology. 2015;62(138):368\u201372.","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"3458_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/eji.201040639","volume":"41","author":"HS TWU Y C, GOLD M R, TEH","year":"2011","unstructured":"TWU Y C, GOLD M R, TEH HS. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8\u2009+\u2009T cells [J]. Eur J Immunol. 2011;41(2):335\u201344.","journal-title":"Eur J Immunol"},{"key":"3458_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.arbres.2020.07.038","volume":"57","author":"C CILL NIZ","year":"2021","unstructured":"CILL NIZ C, TORRES A, GARCIA-VIDAL C, et al. The value of C-Reactive protein-to-lymphocyte ratio in Predicting the Severity of SARS-CoV-2 pneumonia [J]. Arch Bronconeumol. 2021;57:79\u201382.","journal-title":"Arch Bronconeumol"},{"issue":"10","key":"3458_CR16","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/jmv.25819","volume":"92","author":"LAGUNAS-RANGEL F","year":"2020","unstructured":"LAGUNAS-RANGEL F, A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis [J]. J Med Virol. 2020;92(10):1733\u20134.","journal-title":"J Med Virol"},{"key":"3458_CR17","first-page":"329","volume":"16","author":"ME BUYUKBAYRAM","year":"2024","unstructured":"BUYUKBAYRAM ME, HANNARICI Z, DUZKOPRU Y, et al. The effect of C-Reactive Protein\/Lymphocyte ratio (CLR) on PFS in metastatic breast Cancer patients treated with CDK4\/6 inhibitors: a novel biomarker [J]. Breast Cancer (Dove Med Press). 2024;16:329\u201339.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"3458_CR18","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1080\/21655979.2021.1960768","volume":"12","author":"Y MENG","year":"2021","unstructured":"MENG Y, LONG C, HUANG X, et al. Prognostic role and clinical significance of C-reactive protein-lymphocyte ratio in colorectal cancer [J]. Bioengineered. 2021;12(1):5138\u201348.","journal-title":"Bioengineered"},{"key":"3458_CR19","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.2147\/OTT.S167857","volume":"11","author":"M LIAO","year":"2018","unstructured":"LIAO M, CHEN P, LIAO Y, et al. Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resection [J]. Onco Targets Ther. 2018;11:5591\u2013600.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"3458_CR20","first-page":"3223","volume":"110","author":"X CHEN","year":"2024","unstructured":"CHEN X, LIN Z, CHEN Y, et al. C-reactive protein\/lymphocyte ratio as a prognostic biomarker in acute pancreatitis: a cross-sectional study assessing disease severity [J]. Int J Surg. 2024;110(6):3223\u20139.","journal-title":"Int J Surg"},{"key":"3458_CR21","doi-asserted-by":"crossref","unstructured":"Demirkol ME, Aktas G, Bilgin S et al. C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study. Rev Assoc Med Bras (1992). 2022;68(6):838\u2013841.","DOI":"10.1590\/1806-9282.20220236"},{"key":"3458_CR22","doi-asserted-by":"crossref","unstructured":"Wang J, Li H, Wang X et al. Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017\u20132020. Front Endocrinol (Lausanne). 2024;15:1362396.","DOI":"10.3389\/fendo.2024.1362396"},{"issue":"6","key":"3458_CR23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ EDDOWES","year":"2019","unstructured":"EDDOWES PJ, SASSO M, ALLISON M, et al. Accuracy of FibroScan Controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease [J]. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"issue":"2","key":"3458_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H DEVARBHAVI","year":"2023","unstructured":"DEVARBHAVI H, ASRANI S K, ARAB JP, et al. Global burden of liver disease: 2023 update [J]. J Hepatol. 2023;79(2):516\u201337.","journal-title":"J Hepatol"},{"key":"3458_CR25","doi-asserted-by":"crossref","unstructured":"CORTEZ-PINTO H, CAMILO M E, BAPTISTA A et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? [J]. Clinical nutrition (Edinburgh, Scotland), 1999, 18(6): 353\u20138.","DOI":"10.1016\/S0261-5614(99)80015-6"},{"issue":"5","key":"3458_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"MS RINELLA M E, NEUSCHWANDER-TETRI B A","year":"2023","unstructured":"RINELLA M E, NEUSCHWANDER-TETRI B A, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease [J]. Hepatology (Baltimore MD). 2023;77(5):1797\u2013835.","journal-title":"Hepatology (Baltimore MD)"},{"key":"3458_CR27","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y DUAN","year":"2022","unstructured":"DUAN Y, PAN X. Association of Inflammatory Cytokines with non-alcoholic fatty liver disease [J]. Front Immunol. 2022;13:880298.","journal-title":"Front Immunol"},{"issue":"1","key":"3458_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4103\/jfmpc.jfmpc_887_19","volume":"9","author":"R KUMAR","year":"2020","unstructured":"KUMAR R, PORWAL Y C, DEV N, et al. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian indians: a cross-sectional study [J]. J Family Med Prim care. 2020;9(1):390\u20134.","journal-title":"J Family Med Prim care"},{"issue":"6","key":"3458_CR29","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/hep.29702","volume":"67","author":"W WANG","year":"2018","unstructured":"WANG W, WANG Y, QU C, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response [J]. Hepatology (Baltimore MD). 2018;67(6):2096\u2013112.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"5","key":"3458_CR30","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","volume":"61","author":"M Arrese","year":"2016","unstructured":"Arrese M, Cabrera D, Kalergis AM, et al. Innate immunity and inflammation in NAFLD\/NASH. Dig Dis Sci. 2016;61(5):1294\u2013303.","journal-title":"Dig Dis Sci"},{"key":"3458_CR31","doi-asserted-by":"publisher","first-page":"1389967","DOI":"10.3389\/fimmu.2024.1389967","volume":"15","author":"H GONG","year":"2024","unstructured":"GONG H, HE Q, ZHU L, et al. Associations between systemic inflammation indicators and nonalcoholic fatty liver disease: evidence from a prospective study [J]. Front Immunol. 2024;15:1389967.","journal-title":"Front Immunol"},{"issue":"5","key":"3458_CR32","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S MCPHERSON","year":"2015","unstructured":"MCPHERSON S, HARDY T, HENDERSON E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management [J]. J Hepatol. 2015;62(5):1148\u201355.","journal-title":"J Hepatol"},{"key":"3458_CR33","doi-asserted-by":"crossref","unstructured":"LIU E, LI Q, PAN T, et al. Nicotine Tob research: official J Soc Res Nicotine Tob. 2024;26(6):663\u20138. Association Between Secondhand Smoke Exposure and Nonalcoholic Fatty Liver Disease in the General U.S. Adult Nonsmoker Population [J].","DOI":"10.1093\/ntr\/ntad249"},{"issue":"1","key":"3458_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"D YOUNOSSI Z M, KOENIG A B, ABDELATIF","year":"2016","unstructured":"YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology (Baltimore MD). 2016;64(1):73\u201384.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"6","key":"3458_CR35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","volume":"34","author":"S BALLESTRI","year":"2017","unstructured":"BALLESTRI S, NASCIMBENI F. NAFLD as a sexual dimorphic disease: role of gender and Reproductive Status in the development and progression of nonalcoholic fatty liver disease and inherent Cardiovascular risk [J]. Adv Therapy. 2017;34(6):1291\u2013326.","journal-title":"Adv Therapy"},{"issue":"1","key":"3458_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/2050640616646528","volume":"5","author":"CHAN W K","year":"2017","unstructured":"CHAN W K, NIK MUSTAPHA N R, WONG G L, et al. Controlled attenuation parameter using the FibroScan\u00ae XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population [J]. United Eur Gastroenterol J. 2017;5(1):76\u201385.","journal-title":"United Eur Gastroenterol J"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03458-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T10:03:00Z","timestamp":1735034580000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03458-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03458-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the National Center for Health Statistics (NCHS) Ethics Review Board and all participants signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Author declares no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of competing interest"}},{"value":"Shi Ping Hu, E-mail: 2898281633@qq.com.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Corresponding author"}}],"article-number":"475"}}